Hyponatremia is a complex process caused by dysregulation of total body sodium and total body water that can be seen in hypovolemic, euvolemic, and hypervolemic states. Rapid correction of hyponatremia can also lead to serious complications. The development of V2 antagonists, such as tolvaptan, has changed and simplified the management of dilutional hyponatremia by allowing the targeting of antidiuretic hormone (ADH) action and blocking its effect on the V2 receptor. This will decrease the synthesis and relocation of aquaporin 2 to the cortical collecting duct apical membrane. Tolvaptan is approved to be used in euvolemic and hypervolemic hyponatremia, specifically in the syndrome of inappropriate antidiuretic hormone secretion and heart failure. The SALT-1 and SALT-2 studies suggested a starting dose of 15 mg of tolvaptan based on pharmacokinetic data, and while this is an effective dose, multiple studies have shown that patients can overcorrect with this starting dose. At least 1 case of osmotic demyelination - the dreaded complication of overly rapid hyponatremia correction - has been observed with tolvaptan use. While strategies for rapid attenuation of this overcorrection exist, and are discussed, starting tolvaptan at a lower dose of 7.5 mg initially and up-titrating even within the first day is another strategy that can avoid overcorrection. This was noted to be especially important in cases of hyponatremia due to the syndrome of inappropriate ADH secretion. We note that this approach can more slowly correct the hyponatremia with less attendant neurological risks than the currently recommended minimum starting dose of tolvaptan.
Therapy for hypervolemic and euvolemic hyponatremia, in particular the syndrome of inappropriate antidiuretic hormone secretion (SIADH), was improved with the development of the targeted vasopressin type 2 (V2) receptor antagonist tolvaptan. This agent works by directly blocking the receptor on which vasopressin acts, which is also known as antidiuretic hormone (ADH). It acts as a competitive inhibitor of ADH binding to the binding site of the V2 receptor and prevents intracellular signal transduction via intracellular cyclic adenosine mono phosphate. This, in turn, decreases the synthesis and relocation of aquaporin 2 to the cortical collecting duct apical membrane (1) , which results in decreased reabsorption of free water into the cortical collecting duct cells, decreased free water reabsorption into circulation, and increased free water clearance. Hyponatremia as a condition must be corrected very carefully, due to the danger of a rapid change between serum osmolality and neuron intracellular osmolality (2, 3) . If serum osmolality drops relative to cerebrospinal fluid (CSF) osmolality then cerebral edema can develop. If the process is chronic >48 hours, the brain degrades organic osmoles to equalize the osmolality between CSF and serum. Conversely, if serum osmolality rises rapidly relative to CSF osmolality, water loss from brain cells can result in osmotic demyelination syndrome (ODS). This is because the organic osmoles that act as a buffer against CSF osmolal changes are only slowly regenerated by brain cells over several days (2) . This is a common issue faced by nephrologists and clinicians of other disciplines, since hyponatremia is one of the most common electrolyte abnormalities observed in inpatient populations. In the USA, one study estimated its prevalence in the general population at 1.72% (4). In intensive care unit (ICU) patients, hyponatremia was noted to be even more prevalent, with some studies citing a prevalence of 34.3% (5) . Excess mortality due to hyponatremia has variably been estimated from a 5% to 15% increase over mortality caused by baseline conditions alone (6) .
Hazards associated with hyponatremia include falls (7) , osteoporosis (8, 9) , and neurological sequelae ranging from confusion to seizures and coma due to cerebral edema at the opposite extreme (2). However, the correction of hyponatremia needs to be conducted with care and within the established guidelines for slow correction (10) . Changes of serum sodium (Na) in patients on controlled infusions of isotonic or hypertonic fluid can be greater than predicted (11, 12) . The difficulty in controlling serum Na changes in patients with a longer acting directly targeted drug, such as tolvaptan, can be even more challenging given that urine output and urine composition (including urine osmolality and free water clearance) are changing constantly. Our approach, thus far, has been to monitor urine output and serum Na 6 hours after administration, and to monitor serum sodium changes even more closely (every 4 hours) in patients with a rapid aquaresis (13) . (Please see Fig. 1 for the algorithm depicting the decision regarding the use of vaptans, and the decision regarding the dose to use to treat patient populations).
Aggressive fluid restriction is also not recommended during the first day of therapy, or in patients in whom the drug is used during an acute episode of hyponatremia (1, 14) . Unfortunately, despite these measures, overcorrection of hyponatremia does occur, and though rare, it can carry the risk of devastating complications, such as osmotic demyelination syndrome (15) . It has been recommended that overcorrection be treated as an emergent issue in need of rapid reversal. In the setting of a patient receiving a saline or hypertonic infusion, it can be rapidly discontinued, and hypotonic fluid administration can be given with or without deamino-delta-D-arginine vasopressin (DDAVP) to reverse the overcorrection (16) .
Managing overcorrection with V2 receptor antagonist therapy can be more nuanced. The challenge is that the volume of hypotonic fluid required to keep tolvapatan-treated patients from overcorrecting can be very high (17) . This depends on the degree of aquaresis induced by the drug and the water intake by the individual patient. Additionally, a large volume of parenteral 5% dextrose free water administered in these cases may not be well tolerated in patients with diabetes mellitus. Routine use of DDAVP to manage tolvaptaninduced aquaresis may create an unpredictable situation of a competitive inhibitor and a competitive agonist of the V2 receptor at the cellular level of the cortical collecting duct. It is for this reason that the use of DDAVP in the reversal of tolvaptan-induced sodium overcorrection is not routinely recommended.
Currently, many expert opinions exist on the management of overcorrection in the setting of vaptan use. The majority of these interventions are based on a sound theoretical understanding of renal physiology. Nonetheless, there exists a neednoted by previous studies -for clinical trials to standardize care in these situations (18) . There are also known risk factors for the overcorrection of hyponatremia apart from the agent used to ameliorate it. Generally, the risk of overcorrection increases when the cause of hyponatremia is reversible and attenuates while the patient is also receiving treatment for the hyponatremia (19) .
It is also important to note that not all patients are equally at risk for neurological complications from overcorrection. Known risk factors conferring increased odds of neurological sequelae include female sex, alcoholism, malnutrition, severe burns, concomitant hypokalemia, hypophosphatemia, and severe hyponatremia with serum sodium <105 mg/dL (20) . Also, there are protective factors that prevent osmotic demyelination, including uremia, which acts as a buffer to osmotic changes, despite it being an ineffective osmole (3) .
From a physiological perspective, the reasons tolvaptan or other V2 antagonists can lead to overcorrection are decreased access to water or decreased function of osmoreceptors, leading to thirst, the timing of drug initiation, aggressive water restriction while on the drug, a very high starting urine osmolality, a decreased proportion of total body water, and the practical limitations of urine electrolytes and clinical exam in delineating volume status. With regard to the geriatric population, additional difficulties exist due to decreased or altered organ system function, drug-drug interactions, particularly those that interfere with CYP3A4 of the CYP450 system, a decreased amount of total body water in elderly patients, and patients with changes in expected lean body mass and water composition due to pathology (21) .
The current dosing of tolvaptan is based on the SALT-1 and SALT-2 studies, which were carried out in a large number of patients with euvolemic and hypervolemic hypo-osmolar hyponatremia. Euvolemic patients largely had hyponatremia due to SIADH secretion, since patients with endocrine disease of the adrenal and thyroid glands were excluded. In these trials, the established lowest dose of tolvaptan was 15 mg (1). These trials carefully excluded patients with reversible causes of hyponatremia and hypovolemia as appropriate. Despite the careful construction of these trials, multiple reports of overcorrection with the lowest recommended dose of tolvaptan have been observed since these trials were released. This includes at least one published case report and several abstracts regarding ODS, which had not previously been seen in the SALT-1, SALT-2, and SALTWATER trials (17) . The body of literature includes idiosyncratic reactions of some patients to even miniscule doses of tolvaptan, with one patient requiring a dose as low as 3 mg to avoid overcorrection (22) .
The rates of overcorrection in the SALTWATER trial were low (5/111, 4.5%), and only (4/223, 1.8%) of the pooled population of both SALT studies overcorrected. Other studies have noted higher rates of overcorrection in higher risk populations (23, 24) . This suggests that there are significant differences between these populations and the SALT-1/2 and SALTWATER trial populations (25) . If a lower dose of tolvaptan became available in the USA (7.5mg), these groups could potentially be started on half of that dose at 3.75 mg, which was rarely reported as necessary in the literature (22) .
Low-dose tolvaptan (7.5 mg) use also has been tested in the ICU where it was found to be efficacious in a study of critically ill patients. The dose in this study was not standardized, with some receiving 7.5 mg and some receiving 15 mg; it was noted that the rate of overcorrection >12 meq/L/day occurred in approximately 10.5% of cases. The number of patients receiving 7.5 mg with an exaggerated aquaresis was not reported (24) . A similar presentation from the UK's National Health Service showed overcorrection with low-dose 7.5 mg tolvaptan in 4 of 28 high-risk cases (14%) with the correction of >12 meq/L/ day (23) . The rate of overcorrection in this population is higher than the aforementioned SALT/SALTWATER trials, which again suggests that critically ill and SIADH patients are at a higher risk for an exaggerated response to vaptan therapy.
The risks of overcorrection of hyponatremia are clear, and there is increasing debate about the risks of undercorrection in an era where recommendations are steadily pointing to lower maximum daily delta sodium goals. The difficulty in maintaining a balancing act of appropriate correction while minimizing the risk of overcorrection has been noted in the literature (26) .
In general, it has been established that the most severe neurological consequences of hyponatremia due to cerebral edema can be abated with a rapid increase of only 4-6 meq of serum sodium, with maintenance of the serum sodium remaining at that level (27) . Unpublished abstracts from the endocrine society have noted that intermittent tolvaptan 7.5 mg has been used to correct hyponatremia even on an outpatient basis (28) . There are other reports of the largescale use of low-dose tolvaptan in Japan, where its manufacturer, Otsuka, has introduced low-dose 7.5 mg tablets, given the smaller volume of distribution in that population (29) .
It may be necessary to re-dose a low-dose tolvaptan regimen if no effect on the serum sodium or urine osmolality is noted. It is reasonable to test the urine 6 hours later to assess the vasopressin inhibition, as evidenced by reduced urine osmolality. If the urine osmolality remains >300 mosm without significant change of serum sodium, it is reasonable to re-dose another 7.5 mg of tolvaptan and monitor the serum sodium while titrating the dose to effect depending on the response.
Based on our observations, plus the physiology, the data from the Japanese patient population, and the data from other studies, that we recommend that selected high-risk patients be started on a lower dose of tolvaptan therapy (7.5 mg). These include patients who are elderly, patients with a smaller expected volume of total body water, patients with SIADH (30), and patients with increased risks for a robust aquaresis due to reduced CYP 3A4 activity or those taking CYP3A4-inhibiting medications (31) . Additionally, other high-risk patients are those who are at increased risk for ODS based on the defined risk factors.
The management of serum sodium is complex and while tolvaptan presents a useful tool in the armamentarium, it is not without its own risks, as outlined above. The axiom of start low and go slow, with regards to drug dosing, is quite pertinent in the management of hyponatremia as well as many other disorders in geriatric and chronically ill patients. Future directions will include comparing the rates of overcorrection of different doses of tolvaptan and other vaptans in high-risk populations, and comparing the risk of overcorrection with the time of drug administration, which may predispose patients to lower water intake in the setting of late administration of a V2 antagonist.
